Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis

2014271 citationsJournal Article

Authors

Per Soelberg Sørensen · GlaxoSmithKline (India)

Steen Lisby · GlaxoSmithKline (United States)

Richard Grove · Genmab (Denmark)

Frederick J. Derosier · Danish Multiple Sclerosis Center

Steve Shackelford · Rigshospitalet

Eva Havrdová · GlaxoSmithKline (United Kingdom)

Jelena Drulović

Abstract

This study provides Class II evidence that in patients with RRMS, ofatumumab compared with placebo does not increase the number of serious adverse events and decreases the number of new MRI lesions.

Topics & Keywords

Multiple Sclerosis Research Studies Peripheral Neuropathies and Disorders Rheumatoid Arthritis Research and Therapies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Neurology

Volume 82, Issue 7, pp. 573-581

DOI: 10.1212/wnl.0000000000000125

Field-Weighted Citation Impact: 23.00